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New-Onset Atrial Fibrillation is Associated With Cardiovascular
Events Leading to Death in a First Time Myocardial Infarction
Population of 89 703 Patients With Long-Term Follow-Up:
A Nationwide Study
Casper N. Bang, MD, PhD; Gunnar H. Gislason, MD, PhD; Anders M. Greve, MD; Christian A. Bang, MD; Alexander Lilja, MD;
Christian Torp-Pedersen, MD, DMSc; Per K. Andersen, DMSc, PhD; Lars Køber, MD, DMSc; Richard B. Devereux, MD;
Kristian Wachtell, MD, PhD, DMSc
Background-—New-onset atrial ﬁbrillation (AF) is reported to increase the risk of death in myocardial infarction (MI) patients.
However, previous studies have reported conﬂicting results and no data exist to explain the underlying cause of higher death rates
in these patients.
Methods and Results-—All patients with ﬁrst acute MI between 1997 and 2009 in Denmark, without prior AF, were identiﬁed from
Danish nationwide administrative registers. The impact of new-onset AF on all-cause mortality, cardiovascular death, fatal/nonfatal
stroke, fatal/nonfatal re-infarction and noncardiovascular death, were analyzed by multiple time-dependent Cox models and
additionally in propensity score matched analysis. In 89 703 patients with an average follow-up of 5.03.5 years event rates were
higher in patients developing AF (n=10 708) versus those staying in sinus-rhythm (n=78 992): all-cause mortality 173.9 versus
69.4 per 1000 person-years, cardiovascular death 137.2 versus 50.0 per 1000 person-years, fatal/nonfatal stroke 19.6/19.9
versus 6.2/5.6 per 1000 person-years, fatal/nonfatal re-infarction 29.0/60.7 versus 14.2/37.9 per 1000 person-years. In time-
dependent multiple Cox analyses, new-onset AF remained predictive of increased all-cause mortality (HR: 1.9 [95% CI: 1.8 to 2.0]),
cardiovascular death (HR: 2.1 [2.0 to 2.2]), fatal/nonfatal stroke (HR: 2.3 [2.1 to 2.6]/HR: 2.5 [2.2 to 2.7]), fatal/nonfatal
re-infarction (HR: 1.7 [1.6 to 1.8]/HR: 1.8 [1.7 to 1.9]), and non- cardiovascular death (HR: 1.4 [1.3 to 1.5]) all P<0.001).
Propensity-score matched analyses yielded nearly identical results (all P<0.001).
Conclusions-—New-onset AF after ﬁrst-time MI is associated with increased mortality, which is largely explained by more
cardiovascular deaths. Focus on the prognostic impact of post-infarct AF is warranted. ( J Am Heart Assoc. 2014;3:e000382 doi:
10.1161/JAHA.113.000382)
Key Words: cardiovascular mortality • mortality • myocardial infarction • new-onset atrial ﬁbrillation • re-myocardial
infarction • stroke
N ew-onset atrial ﬁbrillation (AF) is a common complica-tion in post-myocardial infarction (MI) patients, which
even in its paroxysmal stage independently predicts adverse
outcome.1–4 This fact indicates that AF in post-MI patients is
an ominous sign, which should be prevented and promptly
treated if detected. However, the prediction of new-onset AF
is difﬁcult, because the mechanisms that promote the
development of AF in the MI setting are complex and
multifactorial, and our understanding of the pathophysiology
remains incomplete.5–7 Similarly, and despite its frequent
occurrence, very limited data exist on whether there are
differences in competing causes of death in MI patients with
AF versus those without AF,5–7 and very few have performed
analysis with AF as a time-dependent variable on long-time
follow-up.3 Moreover, only 1 trial has investigated the impact
of AF on re-MI in post-MI patients.8
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Therefore, the aims of this study were ﬁrst to examine
whether new-onset AF was predictive of all-cause mortality in
ﬁrst-time MI patients and whether this could be explained by an
increase in cardiovascular mortality; and second, to study the
general causes of new-onset AF-related death, including risks of
dying from stroke or re-infarction and noncardiovascular death
during long-time follow-up in a large nationwide cohort of
patients discharged after ﬁrst-time MI in Denmark.
Methods
Since 1978, the Danish National Patient Registry has registered
all hospital admissions as well as diagnoses obtained in
outpatient clinics in Denmark. Each admission is registered
with 1 primary diagnosis and 1 or more secondary diagnoses
according to the International Classiﬁcation of Diseases (ICD),
until 1994 the ICD-8 and from1994 the ICD-10. Since 1995, the
Danish Registry of Medicinal Product Statistics (national
prescription registry) has kept records of every drug prescrip-
tion dispensed from pharmacies in Denmark. Each medication
is classiﬁed by the international Anatomical Therapeutical
Chemical system, and the registry also includes information
about the date of dispensing, formulation, strength, and
quantity dispensed. Information on patients’ vital status (dead
or alive) was obtained from the civil registration system through
Statistics Denmark. In Denmark, every resident is provided with
a permanent and unique civil registration number that enables
linkage between these administrative registries.
Population
From the National Patient Registry we identiﬁed all patients,
aged ≥30 years, hospitalized with acute MI (ICD-10 code I21 to
I22) for the ﬁrst time between 1997 and 2009. The diagnosis of
acute MI and endpoints has been validated in the National
Patient Registry, with a sensitivity of 91% and predictive value of
93%.9 A detailed description of patient selection has been
published previously.10 All patients who were alive at discharge
were included in the present study. The primary outcome was
fatal and nonfatal stroke, fatal and nonfatal re-infarction or
cardiovascular death, noncardiovascular death and ﬁnally all-
cause mortality in respect to new-onset AF following ﬁrst-time
MI. Patients with a history of AF were excluded.
Atrial Fibrillation Ascertainment
Patients with atrial ﬂutter were considered to have AF. From
the National Patient Registry we identiﬁed all patients with
new-onset AF and atrial ﬂutter (ICD-10 code 427.93, 427.94,
I48) between 1997 and 2009. The AF diagnosis in the registry
was based on admission for AF or if AF was recorded during
hospital admission for other disease. All AF episodes, whether
permanent or paroxysmal, were veriﬁed on a 12-lead electro-
cardiogram. The diagnosis AF has previous been validated,
with a speciﬁcity of 99%.11
Drug Use
Since 1995, the Danish Registry of Medicinal Product
Statistics has registered all prescriptions dispensed from
Danish pharmacies. In Denmark the national health security
system covers all inhabitants and partially reimburses drug
expenses (with a maximum copayment for each individual of
US$ 500 a year). Therefore, pharmacies are required to
register all prescriptions dispensed, which ensure complete
registration, and the reimbursement results in minimal
incentive for patients to obtain medication through other
sources. Coding is done according to the Anatomic Thera-
peutical Chemical (ATC) system. The registry includes infor-
mation about date of dispensing, strength and formulation,
quantity dispensed, and the afﬁliation of the doctor who
issues the prescription.
Comorbidity
Comorbidity was deﬁned from diagnoses at discharge from
index MI as speciﬁed in the Ontario acute MI mortality
prediction rule.12 The comorbidity index was further enhanced
by adding diagnoses from 1 year before the event, as done by
Rasmussen et al13 Diagnoses used in the comorbidity index
are shown in Table 1.
Statistical Analysis
Descriptive data are reported as meanstandard deviation
(SD) or frequencies expressed as percentages. The predictive
value of new-onset AF was assessed using the Cox regression
model with delayed entry (ie, counting the time from new-
onset AF to censoring or event, provided that the analyzed
end point had not occurred before new-onset AF) with
adjustment for age, sex, calendar year, re-infarction, concom-
itant pharmacotherapy, and comorbidity.14 To deal with the
time-to-event bias in the new-onset AF patients we made
Landmark analysis with yearly landmarks including Cox
multiple analysis on all the fatal end points.15,16 To analyze
the impact of age on the outcome we made 2 additional
multiple Cox models with yearly landmarks; ﬁrst a with ﬁxed
age adjustment, and second with increasing age adjustment.
Proportional-hazard assumptions, linearity of continuous vari-
ables and lack of interactions were tested for each model. We
calculated a propensity score for the likelihood of developing
new-onset AF following ﬁrst-time MI by a multiple Cox
regression model using baseline covariates. Using the Greedy
matching macro (http://mayoresearch.mayo.edu/mayo/
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research/biostat/upload/gmatch.sas), we matched each
new-onset AF case to 1 AF-free control from the risk set at
the time of AF on the basis of the linear predictor from the
propensity score Cox model and year of AF-onset. Matched
pairs were then analyzed in a Cox regression model with
delayed entry and with AF as the only covariate. Cumulative
incidence of all-cause mortality as a function of incident new-
onset AF from the Landmark analysis was plotted. The hazard
ratios and conﬁdence interval from each Landmark were
plotted in a forest plot. Interaction was tested among the
Landmarks to test whether there was a difference in outcome
in subsequent years after discharge from MI. Finally, the
cumulative incidence of AF was calculated accounting for the
competing risk of death. A 2-tailed P value <0.05 was
regarded as statistically signiﬁcant in all calculations. SAS
statistical software package version 9.1 for UNIX servers (SAS
Institute Inc) was used for statistical analysis.
Ethics
The Danish Data Protection Agency has approved this study
(ref. 2007-58-0015, int. ref: GEH-2010-001), and data at the
individual level were made available in a manner by which
speciﬁc individuals could not be identiﬁed. Retrospective
register studies do not require ethical approval in Denmark.
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the
manuscript as written.
Results
In all, 89 703 post-MI patients with average follow-up of
5.03.5 years were identiﬁed. During the course of the
study, 10 708 (11.9% or 23.9 per 1000 person-years)
patients developed AF after discharge from the ﬁrst-MI
hospitalization and 78 992 (88.1%) remained in sinus rhythm
(SR). The incidence of new-onset AF decreased each year
after discharge from ﬁrst time MI (Figure 1). A total of 29 695
(33.1%) patients received percutaneous coronary intervention.
A detailed description of baseline characteristics of the study
population and distributions are given in Table 1. Table 2
shows how the covariables affected the rate of AF.
All-Cause Mortality After New-Onset Atrial
Fibrillation
All-cause mortality occurred in 5423 (50.6% or 173.9 per
1000 person-years) versus 26 885 (34.0% or 69.4 per
1000 person-years) among patients with and without new-
onset AF, respectively (Figure 2). In a multiple Cox model,
with new-onset AF inserted as a time-dependent variable,
adjusted for age, gender, year, concomitant medical treat-
ment, and comorbidity there was a signiﬁcant increased all-
cause mortality (HR: 1.89 [95% CI: 1.84 to 1.95], P<0.001) in
patients with new-onset AF. The propensity-score matched
analysis yielded nearly identical results (HR: 1.22 [95% CI:
1.17 to 1.27], P<0.001).
To address survival bias, Landmark analysis with yearly
Landmarks was performed. This showed persistent results
(Figures 3 and 4A). In addition, the Landmark analysis
revealed an increasing risk of mortality during subsequent
Landmarks (P for interaction <0.001, Figure 4A). However,
this association was no longer seen when adjusting each
Landmark to increasing age (Figure 4B).
Cardiovascular Mortality After New-Onset Atrial
Fibrillation
Cardiovascular mortality was registered in 4277 (39.9% or
137.2 per 1000 person-years) versus 19 383 (24.5% or 50.0
per 1000 person-years) patients with and without new-onset
AF, respectively (Figure 2). In multiple Cox models, with new-
onset AF inserted as a time-dependent variable, adjusted for
Table 1. Baseline Characteristics
Characteristic n=89 412
Age, y 67.613
Male, n (%) 57 499 (64.1)
Medical Condition
Cerebral vascular disease, n (%) 3737 (4.2)
Pulmonary vascular disease, n (%) 1293 (1.4)
Cancer, n (%) 1650 (1.8)
Cardiac arrhythmias, n (%) 2854 (3.2)
Acute renal failure, n (%) 684 (0.8)
Chronic renal failure, n (%) 1079 (1.5)
Diabetes with complications, n (%) 3905 (4.4)
Pulmonary oedema, n (%) 863 (1.0)
Shock, n (%) 809 (0.9)
Peptic ulcer, n (%) 1258 (1.4)
Prescribed Drugs
Beta blocker, n (%) 66 734 (74.4)
Ace-inhibitor, n (%) 40 065 (44.7)
Acetylsalicylacid, n (%) 51 653 (57.6)
Clopidogrel, n (%) 40 383 (45.0)
Antidiabetic drugs, n (%) 10 769 (12.0)
Loop diuretics, n (%) 32 906 (36.7)
Digitalis, n (%) 6220 (6.9)
Statins, n (%) 56.044 (62.5)
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age, gender, year, concomitant medical treatment, and
comorbidity there was a signiﬁcant increased cardiovascular
mortality (HR: 2.09 [95% CI: 2.01 to 2.16], P<0.001) in
patients with new-onset AF. The propensity-score matched
analysis yielded nearly identical results (HR: 1.24 [95% CI:
1.24 to 1.36], P<0.001).
Fatal Stroke After New-Onset of Atrial Fibrillation
Fatal stroke was registered in 610 (5.7% or 19.6 per
1000 person-years) versus 2414 (3.1% or 6.2 per 1000 per-
son-years) among patients with and without new-onset AF,
respectively (Figure 2). Nonfatal stroke was registered in 606
(5.6% or 19.9 per 1000 person-years) versus 2172 (0.3% or
5.6 per 1000 person-years) among patients with and without
new-onset AF, respectively (Figure 2). In multiple Cox model,
with new-onset AF inserted as a time-dependent variable,
adjusted for age, gender, year, concomitant medical treat-
ment and comorbidity; there was a signiﬁcant increased risk
of both fatal and nonfatal stroke after new-onset AF (HR: 2.34
[95% CI: 2.12 to 2.57], P<0.001 and HR: 2.47 [95% CI: 2.24 to
2.73], P<0.001 respectively). Propensity-score matched
analysis on fatal-stroke yielded nearly identical results.
Fatal Re-Infarction After New-Onset Atrial
Fibrillation
Fatal re-infarction was registered in 905 (8.5% or 29.0 per
1000 person-years) versus 5502 (7.0% or 14.2 per
1000 person-years) among patients with and without new-
onset AF, respectively (Figure 2). Nonfatal re-infarction was
registered in 1521 (14.2% or 60.7 per 1000 person-years)
versus 12 444 (15.8% or 37.9 per 1000 person-years)
Figure 1. Cumulative incidence of new-onset AF after myocardial infarction with death
as competing event. AF indicates atrial ﬁbrillation; MI, myocardial infarction.
Table 2. Co-Variables Contribution to Atrial Fibrillation*
Characteristic Hazard Ratio Conﬁdence Interval P Value
Age 1.041 1.039 to 1.043 <0.001
Male gender 0.949 0.906 to 0.983 <0.001
Medical Condition
Cerebral vascular
disease
0.930 0.846 to 1.022 0.196
Pulmonary vascular
disease
1.065 0.914 to 1.240 0.184
Cancer 0.975 0.836 to 1.137 0.855
Cardiac arrhythmias 1.532 1.408 to 1.667 <0.001
Acute renal failure 1.291 1.054 to 1.582 0.006
Chronic renal failure 1.282 1.027 to 1.512 0.002
Diabetes with
complications
0.971 0.873 to 1.080 0.759
Pulmonary oedema 1.054 0.890 to 1.249 0.585
Shock 1.003 0.828 to 1.216 0.995
Peptic ulcer 1.102 0.949 to 1.280 0.199
Prescribed Drugs
Beta blocker 0.943 0.902 to 0.985 0.038
Ace-inhibitor 1.027 0.987 to 1.070 0.011
Acetylsalicylacid 0.925 0.888 to 0.964 <0.001
Clopidogrel 0.889 0.844 to 0.936 0.001
Antidiabetic drugs 1.082 1.015 to 1.154 0.003
Loop diuretics 1.470 1.408 to 1.535 <0.001
Digitalis 2.867 0.851 to 0.935 <0.001
Statins 0.892 0.851 to 0.935 0.002
*Based on results from propensity score from Cox multiple regression analysis.
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among patients with and without new-onset AF, respectively
(Figure 2). In multiple Cox models, with new-onset AF
inserted as a time-dependent variable, adjusted for age,
gender, year, concomitant medical treatment, and comor-
bidity there was a signiﬁcant increase of both fatal and
nonfatal re-infarction after new-onset AF (HR: 1.67 [95% CI:
1.55 to 1.80], P<0.001 and HR: 1.79 [95% CI: 1.69 to 1.89],
P<0.001 respectively).
Non-Cardiovascular Mortality After New-Onset
Atrial Fibrillation
Non-cardiovascular mortality was registered in 1146 (10.7%
or 38.8 per 1000 person-years) versus 7502 (9.5% or 19.4
per 1000 person-years) among patients with and without
new-onset AF, respectively (Figure 2). In multiple Cox models,
with new-onset AF inserted as a time-dependent variable,
adjusted for age, gender, year, concomitant medical treat-
ment, and comorbidity there was an increased risk of
noncardiovascular mortality (HR: 1.43 [95% CI: 1.34 to
1.53], P<0.001) in patients with new-onset AF. To address
the cause of increased risk of noncardiovascular mortality, an
interaction analysis with PCI was made. This showed a
signiﬁcant lower risk of noncardiovascular mortality in non-
PCI treated patients with new-onset AF compared to PCI
treated patients (HR: 1.42 [95% CI: 1.33 to 1.53]; (HR: 1.55
[95% CI: 1.30 to 1.86], P for interaction <0.001).
Discussion
This study is, to the best of our knowledge, the ﬁrst study to
examine the associations of new-onset AF with speciﬁc causes
of death in a large contemporary post-MI population. Second,
A
B
Figure 2. Incidence of end points among patients with and without
new-onset atrial ﬁbrillation. A, Fatal end points. B, Nonfatal end
points. AF indicates atrial ﬁbrillation; CV, cardiovascular; MI,
myocardial infarction.
Figure 3. Landmark analysis freedom from all-cause mortality with new-onset atrial ﬁbrillation after
myocardial infarction compared with remaining in sinus rhythm. AF indicates atrial ﬁbrillation; CI,
conﬁdence interval; HR, hazard ratio.
DOI: 10.1161/JAHA.113.000382 Journal of the American Heart Association 5
New-Onset AF in MI and Outcome Bang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 7, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
this study adds information on the impact of new-onset AF on
nonfatal cerebral stroke and nonfatal re-MI in a large cohort of
ﬁrst-timeMI patients with long-term follow-up. Themain results
of the study were: (1) that new-onset AF is associated with an
increased risk of all-cause mortality, fatal and nonfatal stroke,
fatal and nonfatal re-infarction, cardiovascular mortality and
non-cardiovascular mortality; and (2) rate of new-onset AF
decreased each year after discharge from ﬁrst-time MI,
however the mortality increased with subsequent years.
New-Onset AF and Myocardial Infarction
In accordance with previous studies, incidence rate of patients
admitted for AF was higher after MI discharge (23.9 per
1000 person-years) compared to the background population in
Denmark of similar age (5 to 7 per 1000 person-years).11
Studies have suggested that increases in atrial pressure can
occur in relation to MI either caused by atrial ischemia,5,6
increased LV ﬁlling pressure or LV pumping become
affected. 7,17 Moreover, AF in MI patients has been associated
with a variety of clinical risk factors including increased age and
history of hypertension and diabetes, kidney dysfunction, and,
in particular, the presence of heart failure symptoms and left
ventricular dysfunction.17–19 However, there is also evidence to
suggest that AF in MI setting is seemingly independent of age,
heart failure, and ventricular dysfunction.20
All-Cause Mortality After New-Onset AF
The observed rate of all-cause mortality among patients who
developed new-onset AF in this study (173.9 per 1000 per-
son-years) is higher than that reported in patients who
developed new-onset AF in the Danish background population
(2.84 to 3.54 per 1000 patient-years).21 Nevertheless, even
after adjustment for several risk factors, new-onset AF was
independently predictive of all-cause mortality in the present
study. This is in accordance with the Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries (GUSTO) I study22 that showed higher 1-
year mortality in post-MI patients with AF compared to
patients without AF. Increased long-term all-cause mortality in
patients with AF in the setting of MI has also been veriﬁed in
the Optimal Trial in Myocardial Infarction with the Angiotensin
II Antagonist Losartan (OPTIMAAL),23 Trandolapril Cardiac
Evaluation (TRACE)20 and VALsartan In Acute myocardial
iNfarcTion (VALIANT)24 studies.
The Cause of Death in MI Patients With and
Without New-Onset AF
It has been demonstrated that AF can facilitate ventricular
arrhythmias,25–27 which could explain the increased risk of all-
cause mortality after new-onset AF in MI patients. However,
to the best of our knowledge, no data exist on the cause of
death in MI patients with and without new-onset AF. Pedersen
et al28 reported increased risk of all-cause and cardiovascular
mortality including sudden cardiac death in MI patients with
AF. Unfortunately, they did not explore speciﬁc causes of
death, did not exclude patients with previous AF and did not
analyze AF as a time-dependent variable. Thus, the present
study demonstrated for the ﬁrst time that MI patients with
new-onset AF have an increased risk of dying from stroke and
re-infarction. Consistent with our data, the OPTIMAAL study23
showed an increased risk of stroke associated with AF in
patients with MI and left ventricular dysfunction. Also the
GUSTO I study22 showed an increased risk of stroke in
patients with AF after MI. The observed increases in risks of
fatal and nonfatal stroke are probably to a large extent
explained by the well-established association of increased
thromboembol in AF. This raises the question whether
post-AMI patients with transient AF should be prescribed
A
B
Figure 4. Subsequently increased all-cause mortality using yearly
landmarks and multiple Cox. A, With ﬁxed age adjustment. B, With
increasing age adjustment.
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anticoagulation similar to patients with primary AF and for
how long?
Some studies have argued that AF is merely a risk marker
of death, and not a causal mediator of MI.29,30 However, there
is evidence to suggest AF is associated with impairment of
endothelial function even in the absence of heart failure or
hypertension which could explain the increased incidence of
AF associated with ischemia-reperfusion injury after MI.31
Interestingly, inﬂammation has been demonstrated to be
important not only in AF but also in MI pathophysiology.32,33
C-reactive protein (CRP) has been shown to reduce nitric
oxide production in endothelial cells and increase endothelial
expression of adhesion molecules.33 It also plays a crucial role
in chemotaxis of monocytes and foam cell formation in
atherosclerotic plaques and enhances vasoreactivity of
unstable plaques.33 This could partly explain the associations
among MI, new-onset AF, and re-MI, and support the idea that
AF reﬂects an underlying disease in the heart.
Non-Cardiovascular Mortality After New-Onset AF
In our study we found that new-onset AF was associated with
noncardiovascular mortality. To a large extent, this could be
explained by the therapeutic challenge with the need of both
vitamin K antagonists (VKAs) and 2 antiplatelet therapy to
prevent stroke and further coronary events in the patients with
new-onset AF, which we have shown to be associated with
increased risk of fatal and nonfatal bleeding.34 This is
supported by the interaction and lower risk of noncardiovas-
cular mortality in non-PCI treated patients with new-onset AF in
the present study. These results imply that new-onset AF in MI
patients is a cardiovascular disease and the independent
relation to adverse cardiovascular prognosis disproves that
new-onset AF only reﬂects age, gender, an increased or general
disease throughout the body such as cancer, chronic kidney,
and/or lung diseases. In addition, you could imagine that AF
makes physiologic stresses from other conditions harder to
tolerate due to poor heart rate regulation and decrease in
cardiac output in some patients, which would make new-onset
AF patients more vulnerable to other diseases.
Increasing Mortality Despite Decreasing
New-Onset AF After Discharge
This study revealed that there is a subsequently increasing risk
of mortality in the later years after discharge from ﬁrst-time MI,
which was mainly due to increasing age. This is supported by
earlier observations including addition of age in CHA2DS2-VASc
score (Congestive heart failure, Hypertension, Age ≥75 years,
Diabetes mellitus, Stroke/TIA, Vascular disease, Aged 65 to
74 years and female Sex [1 point for presence of each, except
for 2 points for age ≥75 years and stroke/TIA]; score range
from 0 to 6).35,36 The decreasing rate of new-onset AF after
discharge could be caused by patients’ immediate atrial
ischemia5,6 or backward failure from an affected LV pump,7,17
or simply that the sickest patient dies earlier, leaving increas-
ingly healthy patients alive with lower risk of new-onset AF.
Strengths and Limitations
Our study suffers the limitations with any analysis of
longitudinal registry data. However, the completeness of
data, which enabled comprehensive follow-up for 10 years,
adds strength to this study. The Danish National Patient
Registry keeps records on discharge diagnosis from all
hospitals in Denmark, and the present study thus avoids
selection bias, which may be present in surveys that are
based on selected centers. Furthermore, the Danish National
Patient Registry as well as the national prescription registry
has been shown to be accurate.9,11,37 The Danish healthcare
system is government ﬁnanced, which secures equal access
to health care for all inhabitants free of charge, regardless of
socioeconomic status. The present study based on registries
did not include clinical data and some comorbid status, most
importantly, hypertension, ejection fraction, MI severity, and
heart failure, which are known to be associated with risk of
developing AF, stroke, MI, and death. This, of course, was a
limitation. In addition, we were not able to subdivide AF
patients into groups according to the severity or persistence
of the arrhythmia that would have allowed us to distinguish
between patients with low risk and patients with even worse
prognosis. We have addressed issues of potential bias and
baseline imbalances between the groups, by performing 3
different sensitivity analyses; (1) a multiple model adjusting
for potential confounders; (2) time-dependent variable analy-
sis; and (3) a propensity score-matched analysis. New-onset
AF, whether paroxysmal or persistent, was identiﬁed from the
National Patient Registry. AF diagnosis is in this registry
based on admission for AF and AF recorded in outpatient
clinics or during hospital admission for other reasons. This
method leaves episodes of paroxysmal AF without need of
hospital admission undetected. Thus, our method may have
underestimated AF occurrence and primarily detected symp-
tomatic AF.
Conclusions
This study shows that MI patients with new-onset AF have an
increased risk of all-cause mortality, which to a large extent is
caused by cardiovascular mortality. This implies that new-
onset AF after MI should be seen as an “adverse prognostic
sign” which should remind the physician to monitor and treat
underlying disease; in particular cardiovascular, as soon as
possible after new-onset AF has occurred.
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